Dynavax Technologies Corp. (DVAX)

6.92
NASDAQ : Health Technology
Prev Close 6.53
Day Low/High 6.49 / 6.94
52 Wk Low/High 2.60 / 12.42
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 83.87M
Market Cap 547.64M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Navigate Choppy Investment Waters With Good Trade Management

Navigate Choppy Investment Waters With Good Trade Management

The inconsistency makes stock picking difficult, but there are buying opportunities because of it.

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

3 Small Biotechs on the FDA Summer Calendar

3 Small Biotechs on the FDA Summer Calendar

Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

2 Questions From the Biotech Mailbag

2 Questions From the Biotech Mailbag

A look at how lawsuits and FDA changes could impact the industry.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

Dynavax Shares Plunge on Rejected Application

Dynavax Shares Plunge on Rejected Application

Shares of the drugmaker were falling on news that U.S. regulators have rejected its Heplisav-B application

Midday Report: Dynavax Slumps on FDA Rejection; U.S. Stocks Fluctuate

Midday Report: Dynavax Slumps on FDA Rejection; U.S. Stocks Fluctuate

U.S. stocks fluctuate as Wall Street picks apart the likely policies of President-elect Donald Trump.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

A Mid-Year Look at 4 Best Ideas Picks

A Mid-Year Look at 4 Best Ideas Picks

I still like and own these small-caps.

4 Possible Biotech M&A Targets

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

And yet, Endocyte has a deep pipeline.

Watching Pernix as Futures Predict an Up Opening

The markets look based on the futures like they're heading for slight upwardly tilt in opening trading. Oil is touching $41 a barrel -- its best level of the year even as Russia's central bank is calling crude's recent rally "unsustainable." Of cour...

Biotech Stocks Are Beginning to Stir

Biotech Stocks Are Beginning to Stir

I am starting to get more confident that the small caps are ready to bounce.

Cashing In on the Biotech Bear Market

Cashing In on the Biotech Bear Market

My 4-Tier approach to deploying new capital in the sector.

3 Scorned Biotechs Destined to Rebound

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.

3 Scorned Biotechs Destined to Rebound

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.